Platelet aggregation in arterial hypertension: Is there a nitric oxide-urea connection?

Clinical and Experimental Pharmacology and Physiology

Volumn 37, Issue 2, 2010, Pages 167-172

  Moss, Monique B ^a   Siqueira, Mariana A ^a   Mann, Giovanni E ^b   Brunini, Tatiana Mc ^a   Mendes Ribeiro, Antônio C ^a,c  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c FEDERAL UNIVERSITY OF THE STATE OF RIO DE JANEIRO   (Brazil)

Author keywords

Essential hypertension; Nitric oxide; Nitric oxide synthase; Platelets; Urea cycle

Indexed keywords

ARGINASE; ARGININE; C REACTIVE PROTEIN; FIBRILLAR COLLAGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; UREA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MALE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; UREA CYCLE;

ADULT; ARGINASE; ARGININE; BLOOD PLATELETS; C-REACTIVE PROTEIN; COLLAGEN; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PLATELET AGGREGATION; UREA;

EID: 75649098636     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2009.05247.x     Document Type: Article

References (47)

1. Lessa I. Epidemiologia da Hipertensão arterial sistêmica e da insuficiência cardíaca no Brasil. Rev. Bras. Hipertens. 2001 8 : 383 392.
2. Rosendorff C, Black HR, Cannon CP et al. Treatment of hypertension in the prevention and management of ischemic heart disease. Circulation 2007 115 : 2761 2788.
3. Nadar SK, Tayebjee MH, Messerli F, Lip GY. Target organ damage in hypertension: Pathophysiology and implications for drug therapy. Curr. Pharm. Des. 2006 12 : 1581 1592.
4. Mendes Ribeiro AC, Brunini TM. l-Arginine transport in disease. Curr. Med. Chem. Cardiovasc. Hematol. Agents 2004 2 : 123 131.
5. Moss MB, Brunini TM, Soares De Moura R et al. Diminished l-arginine bioavailability in hypertension. ClSci. 2004 107 : 391 397.
6. Ozkor MA, Quyyumi AA. TetrahydrobiopterCurr. Hypertens. Rep. 2008 10 : 58 64.
7. Moncada S, Higgs EA. The discovery of nitric oxide and its role in vascular biology. Br. J. Pharmacol. 2006 147 (Suppl. S193 201.
8. Brunini TMC, Mendes-Ribeiro AC, Ellory JC, Mann GE. Platelet nitric oxide synthesis and activation in uremia and malnutrition: A role for l-arginine supplementation in vascular protection? Cardiovasc. Res. 2007 73 : 359 367.
9. Mann GE, Yudilevich DL, Sobrevia L. Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol. Rev. 2003 83 : 183 252.
10. Mehta JL, Chen LY, Kone BC, Mehta P, Turner P. Identification of constitutive and inducible forms of nitric oxide synthase in human platelets. J. Lab. ClMed. 1995 125 : 370 377.
11. +L as the high-affinity transporter for l-arginine in human platelets. Up-regulation of l-arginine influx in uraemia. Pflügers Arch. 1999 438 : 573 575.
12. +L. Pflügers Arch. 2003 445 : 540 546.
13. de Meirelles LR, Mendes Ribeiro AC, Mendes MA et al. Chronic exercise reduces platelet activation in hypertension: Upregulation of l-arginine-nitric oxide pathway. Scand. J. Med. Sci. Sports 2009 19 : 67 74.
14. Minuz P, Patrignani P, Gaino S et al. Determinants of platelet activation in human essential hypertension. Hypertension 2004 43 : 64 70.
15. Blann AD, Nadar S, Lip GYH. Pharmacological modulation of platelet function in hypertension. Hypertension 2003 41 : 1 7.
16. Chicoine LG, Paffett ML, Young TL, Nelin LD. Arginase inhibition increases nitric oxide production in bovine pulmonary arterial endothelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004 287 : L60 8.
17. Morris SM Jr., Kepka DM, Sweeney WE Jr., Avner ED. Abundance of mRNAs encoding urea cycle enzymes in fetal and neonatal mouse liver. Arch. Biochem. Biophys. 1989 269 : 175 180.
18. de la Peña NC, Sosa-Melgarejo JA, Ramos RR, Méndez JD. Inhibition of platelet aggregation by putrescine, spermidine, and spermine in hypercholesterolemic rabbits. Arch. Med. Res. 2000 31 : 546 550.
19. Mendéz JD, Zarzoza E. Inhibition of platelet aggregation by l-arginine and polyamines in alloxan treated rats. Biochem. Mol. Biol. Int. 1997 43 : 311 318.
20. Croce K, Libby P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr. OpHematol. 2007 14 : 49 55.
21. Cottone S, Mulè G, Nardi E et al. Relation of C-reactive protein to oxidative stress and to endothelial activation in essential hypertension. Am. J. Hypertens. 2006 19 : 313 318.
22. Boos CJ, Lip GY. Is hypertension an inflammatory process? Curr. Pharm. Des. 2006 12 : 1623 1635.
23. Nelin LD, Chicoine LG, Reber KM, English BK, Young TL, Liu Y. Cytokine-induced endothelial arginase expression is dependent on epidermal growth factor receptor. Am. J. Respir. Cell Mol. Biol. 2005 33 : 394 401.
24. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report [published erratum appears in JAMA 2003; 290: 197). JAMA 2003 289 : 2560 2572.
25. Riba R, Sharifi M, Farndale RW, Naseem KM. Regulation of platelet guanylyl cyclase by collagen: Evidence that glycoprotein VI mediates platelet nitric oxide synthesis in response to collagen. J. Thromb. Haemost. 2005 94 : 395 403.
26. Roberts W, Riba R, Homer-Vanniasinkam S, Farndale RW, Naseem KM. Nitric oxide specifically inhibits integrin-mediated platelet adhesion and spreading on collagen. J. Thromb. Haemost 2008 6 : 2175 2185.
27. Walter U, Gambaryan S. cGMP and cGMP-dependent protein kinase in platelets and blood cells. Handb. Exp. Pharmacol. 2009 191 : 533 548.
28. Radomski MW, Palmer RM, Moncada S. An l-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc. Natl Acad. Sci. USA 1990 87 : 5193 5197.
29. Sase K, Michel T. Expression of constitutive endothelial nitric oxide synthase in human blood platelets. Life Sci. 1995 57 : 2049 2055.
30. Vignini A, Nanetti L, Moroni C et al. Modifications of platelet from Alzheimer disease patients: A possible relation between membrane properties and NO metabolites. Neurobiol. Aging 2007 28 : 987 994.
31. Persichini T, Cantoni O, Suzuki H, Colasanti M. Cross-talk between constitutive and inducible NO synthase: An update. Antioxid. Redox Signal. 2006 8 : 949 954.
32. Marjanovic JA, Stojanovic A, Brovkovych VM, Skidgel RA, Du X. Signaling-mediated functional activation of inducible nitric-oxide synthase and its role in stimulating platelet activation. J. Biol. Chem. 2008 283 : 28827 28834.
33. Gokce N. l-Arginine and hypertension. J. Nutr. 2004 134 (Suppl. S2807 11.
34. Hong HJ, Hsiao G, Cheng TH, Yen MH. Supplemention with tetrahydrobiopterin suppresses the development of hypertension in spontaneously hypertensive rats. Hypertension 2001 38 : 1044 1048.
35. Rizzo M, Corrado E, Coppola G et al. The predictive role of C-reactive protein in subjects with hypertension and subclinical atherosclerosis. Intern. Med. J. 2009 34 : 20 6.
36. Demougeot C, Pringent-Tessier A, Bagnost T et al. Time course of vascular arginase expression and activity in spontaneously hypertensive rats. Life Sci. 2007 80 : 1128 1134.
37. Zhang C, Hein TW, Wang W et al. Upregulation of vascular arginase in hypertension decreases nitric-oxide-mediated dilatation of coronary arterioles. Hypertension 2004 44 : 935 943.
38. Demougeot C, Pringet-Tessier A, Marie C, Berthelot A. Arginase inhibition reduces endothelial dysfunction and blood pressure rising in spontaneous hypertensive rats. J. Hypertens. 2005 23 : 971 978.
39. Landmesser U, Dikalov S, Price SR et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J. ClInvest. 2003 4 : 51 61.
40. Schulze F, Lenzen H, Hanefeld C et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: Results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am. Heart J. 2006 152 : 493.e1 8.
41. Böger GI, Rudolph TK, Maas R et al. Asymmetric dimethylarginine determines the improvement of endothelium-dependent vasodilation by simvastatin: Effect of combination with oral l-arginine. J. Am. Coll. Cardiol. 2007 49 : 2274 2282.
42. Tsikas D, Böger RH, Sandmann J, Bode-Böger SM, Frölich JC. Endogenous nitric oxide synthase inhibitors are responsible for the l-arginine paradox. FEBS Lett. 2000 478 : 1 3.
43. McBride AE, Silver PA. State of the arg: Protein methylation at arginine comes of age. Cell 2001 106 : 5 8.
44. Kielstein JT, Impraim B, Simmel S et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004 109 : 143 147. (Pubitemid 39140423)
45. Perticone F, Sciacqua A, Maior R et al. Asymmetric dimethylarginine, l-arginine, and endothelial dysfunction in essential hypertension. J. Am. Coll. Cardiol. 2005 46 : 518 523.
46. Brunini T, Moss M, Siqueira M et al. Inhibition of l-arginine transport in platelets by asymmetric dimethylarginine and N-monomethyl-l-arginine: Effects of arterial hypertension. ClExp. Pharmacol. Physiol. 2004 31 : 738 740.
47. de MeirellesLR, Mendes-Ribeiro AC, Santoro MM et al. Inhibitory effects of endogenous l-arginine analogues on nitric oxide synthesis in platelets: Role in platelet hyperaggregability in hypertension. ClExp. Pharmacol. Physiol. 2007 34 : 1267 1271.